Novo Nordisk Cuts U.S. List Prices for Ozempic and Wegovy
Novo Nordisk will list Ozempic, Wegovy and Rybelsus at $675 per month starting Jan. 1, 2027, saying the move aims to improve affordability amid competition and new Medicare pricing.
Overview
Novo Nordisk said it will cut list prices of Ozempic, Wegovy and Rybelsus to $675 per month effective Jan. 1, 2027.
The company said the cuts coincide with new lower Medicare prices and respond to growing competition from Eli Lilly and other GLP-1 makers and calls for lower list prices.
Novo Nordisk said the cuts aim to lower out-of-pocket costs for patients with high-deductible plans and reduce coinsurance burdens, a company executive said.
Novo Nordisk said $675 equals a 50% reduction for Wegovy and a 35% reduction for Ozempic from current list prices, with Wegovy previously listed at $1,349 per month.
On Feb. 23, Novo released late-stage results showing CagriSema reduced body weight 23% versus 25.5% for Eli Lilly's tirzepatide, and Novo said it expects FDA approval by the end of 2026 and a 2027 launch.
Analysis
Center-leaning sources frame the story as a market‑and-policy driven maneuver: language like “slashed” and “intense competition” casts the price cut as strategic, not purely benevolent. Editorial choices elevate company explanations, industry and employer survey data, and competitive study results while emphasizing limited benefit for cash-paying patients to temper applause.
FAQ
Novo Nordisk is reducing prices to enhance affordability amid growing competition from Eli Lilly's GLP-1 medications (Mounjaro and Zepbound) and other competitors entering the market[1]. The company is also responding to calls from private and public payers and patients for lower list prices[3]. Additionally, the price cuts coincide with new lower Medicare pricing for these drugs[4].
Wegovy will see a 50% price reduction to $675 per month (down from approximately $1,349), while Ozempic will see a 35% reduction to the same $675 monthly price[1]. Rybelsus, a pill for type 2 diabetes sometimes used for weight loss, will also be priced at $675 per month[2]. These prices take effect on January 1, 2027.
The price reductions apply to specific doses: Wegovy 2.4 mg injections and 25 mg tablets, Ozempic 0.5 mg, 1 mg, and 2 mg injections, and Rybelsus 7 mg and 14 mg tablets[2]. According to Novo Nordisk's announcement, this decision applies to all doses of these medicines[3].
The lower list prices are specifically intended to benefit patients whose out-of-pocket costs are linked to list price, particularly those with high-deductible health plans and coinsurance benefit designs[3]. However, Novo Nordisk noted that the price reductions do not impact its direct-to-patient discount prices that some customers already receive[1].
Novo Nordisk's price cuts represent a competitive response to Eli Lilly, which sells GLP-1 medications Mounjaro and Zepbound for weight loss[1]. The Danish drugmaker is also competing with other GLP-1 treatments entering the market. Additionally, Wegovy and Ozempic are among drugs offered at discounted prices through Trumprx.gov, a new federal platform launched by the Trump administration[1].
